Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man.

Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W

The Journal of clinical endocrinology and metabolism1 Nov 1992Cited by 72 (Europe PMC)

PMID1430077DOI10.1210/jcem.75.5.1430077PepBankPUB-01430077

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanNon-randomized trialPharmacokinetics
In fasted normal males, IGF-I at 5 micrograms/kg.h produced total plasma IGF-I of 247 +/- 30 ng/ml versus 127 +/- 7 without IGF-I.
In plain wordsIn fasted normal males, the lowest active IGF-I dose produced higher blood IGF-I levels than no IGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTotal plasma IGF-I at low dose
Study
n: not reported in source
Comparator
0 micrograms/kg.h
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
5 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Total plasma IGF-I
247 ng/ml
5 micrograms/kg.h group (SD 30)
Total plasma IGF-I
127 ng/ml
0 micrograms/kg.h group (SD 7)
Source sentences
Summary
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h, resulting in total plasma IGF-I concentrations 127 +/- 7, 247 +…
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007701
02HumanNon-randomized trialPharmacokinetics
In fasted normal males, IGF-I at 7.5 micrograms/kg.h produced total plasma IGF-I of 389 +/- 39 ng/ml.
In plain wordsIn fasted normal males, this IGF-I dose produced higher blood IGF-I levels than no IGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTotal plasma IGF-I at intermediate dose
Study
n: not reported in source
Comparator
0 micrograms/kg.h
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
7.5 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Total plasma IGF-I
389 ng/ml
7.5 micrograms/kg.h group (SD 39)
Total plasma IGF-I
127 ng/ml
0 micrograms/kg.h group (SD 7)
Source sentences
Summary
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h, resulting in total plasma IGF-I concentrations 127 +/- 7, 247 +…
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007702
03HumanNon-randomized trialPharmacokinetics
In fasted normal males, IGF-I at 15 micrograms/kg.h produced total plasma IGF-I of 573 +/- 62 ng/ml.
In plain wordsIn fasted normal males, this IGF-I dose produced higher blood IGF-I levels than no IGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTotal plasma IGF-I at higher dose
Study
n: not reported in source
Comparator
0 micrograms/kg.h
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
15 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Total plasma IGF-I
573 ng/ml
15 micrograms/kg.h group (SD 62)
Total plasma IGF-I
127 ng/ml
0 micrograms/kg.h group (SD 7)
Source sentences
Summary
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h, resulting in total plasma IGF-I concentrations 127 +/- 7, 247 +…
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007703
04HumanNon-randomized trialPharmacokinetics
In fasted normal males, IGF-I at 30 micrograms/kg.h produced total plasma IGF-I of 620 +/- 105 ng/ml.
In plain wordsIn fasted normal males, the highest IGF-I dose produced higher blood IGF-I levels than no IGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTotal plasma IGF-I at highest dose
Study
n: not reported in source
Comparator
0 micrograms/kg.h
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Total plasma IGF-I
620 ng/ml
30 micrograms/kg.h group (SD 105)
Total plasma IGF-I
127 ng/ml
0 micrograms/kg.h group (SD 7)
Source sentences
Summary
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h, resulting in total plasma IGF-I concentrations 127 +/- 7, 247 +…
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007704
05HumanNon-randomized trialEfficacy outcome
IGF-I increased glucose consumption dose dependently in fasted normal males, reaching 6.7 +/- 1.3 mg/kg. min at the highest dose.
In plain wordsIn fasted normal males, higher IGF-I doses increased glucose use.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseGlucose consumption
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 7.5, 15, or 30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Glucose consumption
6.7 mg/kg. min
30 micrograms/kg.h group, up to (SD 1.3)
P value for glucose consumption dose-dependent increase
< 0.001 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
Glucose consumption (euglycemic glucose clamp) increased dose dependently during IGF-I infusion (P < 0.001) up to 6.7 +/- 1.3 mg/kg. min in the 30 micrograms/kg.h group.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007705
06HumanNon-randomized trialEfficacy outcome
IGF-I reduced triglycerides dose dependently in fasted normal males, with a 43% fall at 30 micrograms/kg.h.
In plain wordsIn fasted normal males, higher IGF-I doses reduced triglycerides.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
5, 7.5, 15, or 30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Plasma triglyceride fall
43%
30 micrograms/kg.h group
P value for plasma triglyceride concentration dose-dependent decrease
< 0.03 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
Plasma triglyceride concentrations decreased with increasing doses of IGF-I (P < 0.03); the fall was 43% in the 30 micrograms/kg.h group.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007706
07HumanNon-randomized trialEfficacy outcome
IGF-I at 7.5 micrograms/kg.h reduced free fatty acids by 23% in fasted normal males.
In plain wordsThis IGF-I dose reduced free fatty acids in fasted normal males.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFree fatty acids at intermediate dose
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
7.5 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Plasma free fatty acid decrease
23%
7.5 micrograms/kg.h
Source sentences
Summary
Plasma free fatty acid concentrations decreased during 7.5, 15, and 30 micrograms/kg.h IGF-I by 23%, 34%, and 48%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007707
08HumanNon-randomized trialEfficacy outcome
IGF-I at 15 micrograms/kg.h reduced free fatty acids by 34% in fasted normal males.
In plain wordsThis IGF-I dose reduced free fatty acids in fasted normal males.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFree fatty acids at higher dose
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
15 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Plasma free fatty acid decrease
34%
15 micrograms/kg.h
Source sentences
Summary
Plasma free fatty acid concentrations decreased during 7.5, 15, and 30 micrograms/kg.h IGF-I by 23%, 34%, and 48%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007708
09HumanNon-randomized trialEfficacy outcome
IGF-I at 30 micrograms/kg.h reduced free fatty acids by 48% in fasted normal males.
In plain wordsThe highest IGF-I dose reduced free fatty acids in fasted normal males.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFree fatty acids at highest dose
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Plasma free fatty acid decrease
48%
30 micrograms/kg.h
Source sentences
Summary
Plasma free fatty acid concentrations decreased during 7.5, 15, and 30 micrograms/kg.h IGF-I by 23%, 34%, and 48%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007709
10HumanNon-randomized trialEfficacy outcome
IGF-I reduced beta-hydroxybutyrate dose dependently in fasted normal males.
In plain wordsIn fasted normal males, higher IGF-I doses reduced beta-hydroxybutyrate.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseBeta-hydroxybutyrate
Study
n: not reported in source
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
5, 7.5, 15, or 30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
P value for plasma beta-hydroxybutyrate concentration dose-dependent decrease
< 0.025 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
IGF-I lowered plasma beta-hydroxybutyrate concentrations in a dose-dependent manner (P < 0.025).
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007710
11HumanNon-randomized trialEfficacy outcome
IGF-I reduced plasma leucine dose dependently in fasted normal males.
In plain wordsIn fasted normal males, higher IGF-I doses reduced blood leucine.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseLeucine concentration
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
5, 7.5, 15, or 30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
P value for plasma leucine concentration dose-dependent decrease
< 0.001 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
Plasma concentrations of leucine and alpha-ketoisocaproate decreased dose dependently (P < 0.001 and P < 0.015).
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007711
12HumanNon-randomized trialEfficacy outcome
IGF-I reduced plasma alpha-ketoisocaproate dose dependently in fasted normal males.
In plain wordsIn fasted normal males, higher IGF-I doses reduced blood alpha-ketoisocaproate.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseAlpha-ketoisocaproate
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
5, 7.5, 15, or 30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
P value for plasma alpha-ketoisocaproate concentration dose-dependent decrease
< 0.015 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
Plasma concentrations of leucine and alpha-ketoisocaproate decreased dose dependently (P < 0.001 and P < 0.015).
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007712
13HumanNon-randomized trialEfficacy outcome
IGF-I reduced whole-body leucine flux dose dependently in fasted normal males, with a 41% reduction at 30 micrograms/kg.h.
In plain wordsIn fasted normal males, higher IGF-I doses reduced protein breakdown.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseWhole-body leucine flux
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Whole body leucine flux decrease
41%
30 micrograms/kg.h
Source sentences
Summary
Whole body leucine flux (1-13C-leucine infusion technique) decreased with increasing doses of IGF-I by 41% during 30 micrograms/kg.h, indicating decreased whole body protein breakdown.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007713
14HumanNon-randomized trialEfficacy outcome
IGF-I reduced leucine oxidation dose dependently in fasted normal males, with a 57% reduction at 30 micrograms/kg.h.
In plain wordsIn fasted normal males, higher IGF-I doses reduced leucine breakdown.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseLeucine oxidation
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
Leucine oxidation decrease
57%
30 micrograms/kg.h group
P value for leucine oxidation into 13co2 dose-dependent decrease
< 0.045 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
Leucine oxidation into 13CO2 decreased with increasing doses of IGF-I (P < 0.045) by 57% in the 30 micrograms/kg.h group, suggesting inhibition of irreversible loss of leucine.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007714
15HumanNon-randomized trialEfficacy outcome
IGF-I reduced plasma C-peptide dose dependently in fasted normal males.
In plain wordsIn fasted normal males, higher IGF-I doses reduced C-peptide.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseC-peptide
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 7.5, 15, or 30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
P value for plasma c-peptide concentration dose-dependent decrease
< 0.005 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
Plasma C-peptide and insulin concentrations decreased dose dependently (P < 0.005 and P < 0.02), indicating diminished insulin secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007715
16HumanNon-randomized trialEfficacy outcome
IGF-I reduced plasma insulin dose dependently in fasted normal males.
In plain wordsIn fasted normal males, higher IGF-I doses reduced insulin.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseInsulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 7.5, 15, or 30 micrograms/kg.h · infusion · 8 hAs given in this study (human).
Measurements
P value for plasma insulin concentration dose-dependent decrease
< 0.02 dimensionless
Dose-dependent response across IGF-I infusion doses
Source sentences
Summary
Plasma C-peptide and insulin concentrations decreased dose dependently (P < 0.005 and P < 0.02), indicating diminished insulin secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h
Report a problemFND-0143007716

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.